Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

On December 16, 2025, Galecto, Inc. (Nasdaq: GLTO) announced a significant stock option grant as part of their hiring incentive for a new employee. The Board of Directors approved the issuance of non-qualified stock options for 312,535 shares of common stock under their 2022 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). These options have an exercise price set at $32.00 per share and feature a structured vesting schedule. Specifically, 25% of the options will vest on the first anniversary of the grant date, with the remaining options vesting in monthly increments starting thereafter, contingent upon the employee's continued employment.

Galecto, Inc. is a clinical-stage biotechnology firm focused on developing innovative antibody therapeutics aimed at treating a wide array of hematological cancers. The company's product pipeline is particularly notable for its emphasis on targeting mu-cALR-driven diseases, including essential thrombocythemia and myelofibrosis. Notably, Galecto is anticipating the submission of an Investigational New Drug (IND) application for its lead asset, DMR-001, in mid-2026. This monoclonal antibody is expected to be a leading option for patients, as it is administered subcutaneously and targets mutant CALR.

In addition to DMR-001, Galecto is also advancing GB3226, which is a pioneering preclinical dual inhibitor designed to address multiple genetic subsets of acute myeloid leukemia (AML). As the company progresses its pipeline, stakeholders and potential investors are encouraged to stay informed through regular updates available on their official website, www.galecto.com. For media inquiries, Lia Dangelico from Deerfield Group can be reached, along with investor relations contact Sandya von der Weid from LifeSci Advisors.

Galecto, Inc. (Nasdaq: GLTO) has recently made headlines with the announcement of a significant inducement grant of non-qualified stock options for new employee hiring, potentially signaling robust future growth prospects. This move, as per Nasdaq Listing Rule 5635(c)(4), reflects the company’s commitment to attracting top talent necessary for furthering its clinical-stage pipeline, particularly its innovative therapies targeting hematological cancers.

The grant includes options to purchase 312,535 shares at an exercise price of $32.00, with a structured vesting schedule designed to motivate the new hire to contribute valuably over time—25% vesting after one year, followed by monthly vesting thereafter. This denotes confidence in both the new employee and the company's trajectory moving forward.

Galecto’s expansive pipeline, particularly its lead asset DMR-001, is positioned to make waves in the oncology market with expected filing for IND status by mid-2026. This biopharmaceutical focus on mut-CALR-driven myeloproliferative neoplasms could provide significant competitive advantages as the drug landscape evolves, especially for conditions like essential thrombocythemia and myelofibrosis.

Investors should consider the implications of this inducement grant in the context of potential future stock performance. The issuance of options at a premium price suggests management’s optimism about future valuations. However, given the subcutaneous administration of DMR-001 and Galecto's proprietary technology, key milestones in the next year will be critical in establishing market confidence.

In conclusion, interested investors should monitor Galecto's progress towards clinical filings and market developments closely. While the current option price indicates a premium buy-in, remaining alert to the forthcoming data announcements and the company’s ability to deliver on promises will be fundamental in determining the stock’s potential upside in the coming months.